Toll Free: 1-888-928-9744

Icon Bioscience, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Icon Bioscience, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Icon Bioscience, Inc. - Product Pipeline Review - 2014', provides an overview of the Icon Bioscience, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Icon Bioscience, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Icon Bioscience, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Icon Bioscience, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Icon Bioscience, Inc.'s pipeline products

Reasons to buy

- Evaluate Icon Bioscience, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Icon Bioscience, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Icon Bioscience, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Icon Bioscience, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Icon Bioscience, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Icon Bioscience, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Icon Bioscience, Inc. Snapshot 5
Icon Bioscience, Inc. Overview 5
Key Information 5
Key Facts 5
Icon Bioscience, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Icon Bioscience, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Icon Bioscience, Inc. - Pipeline Products Glance 11
Icon Bioscience, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Icon Bioscience, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Icon Bioscience, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Icon Bioscience, Inc. - Drug Profiles 16
dexamethasone acetate 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
triamcinolone acetonide 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IBI-30090 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
IBI-70090 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
latanoprost 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
melphalan 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Drug for Cornea Transplant Rejection 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drug for Diabetic Macular Edema 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drug for Proliferative Diabetic Retinopathy 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Drug for Wet Age Related Macular Degeneration 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Icon Bioscience, Inc. - Pipeline Analysis 26
Icon Bioscience, Inc. - Pipeline Products by Target 26
Icon Bioscience, Inc. - Pipeline Products by Route of Administration 27
Icon Bioscience, Inc. - Pipeline Products by Molecule Type 28
Icon Bioscience, Inc. - Pipeline Products by Mechanism of Action 29
Icon Bioscience, Inc. - Recent Pipeline Updates 30
Icon Bioscience, Inc. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33
List of Tables
Icon Bioscience, Inc., Key Information 5
Icon Bioscience, Inc., Key Facts 5
Icon Bioscience, Inc. - Pipeline by Indication, 2014 8
Icon Bioscience, Inc. - Pipeline by Stage of Development, 2014 9
Icon Bioscience, Inc. - Monotherapy Products in Pipeline, 2014 10
Icon Bioscience, Inc. - Phase III, 2014 11
Icon Bioscience, Inc. - Phase II, 2014 12
Icon Bioscience, Inc. - Phase I, 2014 13
Icon Bioscience, Inc. - Preclinical, 2014 14
Icon Bioscience, Inc. - Discovery, 2014 15
Icon Bioscience, Inc. - Pipeline by Target, 2014 26
Icon Bioscience, Inc. - Pipeline by Route of Administration, 2014 27
Icon Bioscience, Inc. - Pipeline by Molecule Type, 2014 28
Icon Bioscience, Inc. - Pipeline Products by Mechanism of Action, 2014 29
Icon Bioscience, Inc. - Recent Pipeline Updates, 2014 30 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify